Q1 FY27 results analysis · July 21, 2026

Anthem Biosciences Ltd Q1 FY27 Results Analysis: Revenue Plunges 22.6%, PAT Sinks 12%

−11.7%PAT year on year, Rs. 119.94 Cr
Cofacto ResearchPublished July 21, 20262 min readNegative read
Quick summary

Anthem Biosciences Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 418.22 Cr (-22.58% YoY) and PAT growth of -11.67% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 21, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 418.22 Cr (-22.58% YoY)
PAT (Q1)Rs. 119.94 Cr (-11.67% YoY)
EBITDA margin39.60% (+154 bps YoY)
EPS (Q1)Rs. 2.13 (-12.35% YoY)
Market capRs. 44,579.71 Cr
CMPRs. 791.55

Quarter Snapshot

The company reported a sharp 22.58% YoY revenue decline, the lowest in three quarters, despite improving gross margins due to backward integration. Employee cost escalation and operating deleverage caused PAT to fall 11.67% YoY. Management's prior optimism on restocking was not borne out, and no guidance was provided for FY27.

Key Investment Insights

Key Positives

  • CRDMO gross profit margin expanded 964 bps YoY to 68.15% from 58.51%.
  • Total gross profit margin expanded 778 bps YoY to 65.04%.
  • EBITDA margin on Total Income basis expanded 154 bps YoY to 39.60%.
  • Credit rating upgraded to ICRA AA (Stable) from AA- (Positive).
  • Subsidiary contributed Rs.17.93 Cr PAT, offsetting part of consolidated decline.
  • Net cash of Rs.1,374.3 Cr provides headroom for capex plans.

Risk Factors

  • Revenue declined 22.58% YoY and 31.55% QoQ, the lowest since Q3FY26.
  • Employee cost as % of revenue rose 552 bps YoY to 18.85%, causing operating deleverage.
  • PAT declined 11.67% YoY despite margin expansion, due to fixed-cost burden.
  • Management's prior claim of restocking not visible in revenue numbers.
  • Effective tax rate boosted by deferred tax credit, not sustainable.
  • Promoter group member sold 3.05% stake, reducing holding.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.